Trial ID or NCT#

NCT01268280

Status

NOT RECRUITING

Purpose

The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with generalized myasthenia gravis (MG).

Official Title

A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Yuen So, MD, PhD
Neuromuscular neurologist, Neurophysiologist
Professor of Neurology at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Shirely Paulose
(650) 724-3792